Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3177417 | 0.87 | KMT2A (0.62) | KMT2AEPHX2OPRD1CASP3FABP7 | |
| SCHEMBL2631637 | 0.86 | KMT2A (0.63) | KMT2AEPHX2OPRD1CASP3 | |
| SCHEMBL31652901 | 0.86 | KMT2A (0.56) | KMT2AEPHX2OPRD1CASP3FABP7 | |
| SCHEMBL2744319 | 0.86 | KMT2A (0.55) | KMT2AEPHX2OPRD1CASP3FABP7 | |
| SCHEMBL693419 | 0.85 | KMT2A (0.52) | KMT2AEPHX2OPRD1CASP3FABP7 | |
| SCHEMBL16256817 | 0.85 | KMT2A (0.52) | KMT2AEPHX2OPRD1CASP3FABP7 | |
| SCHEMBL2057615 | 0.85 | KMT2A (0.55) | KMT2AEPHX2OPRD1CASP3FABP7 | |
| SCHEMBL31010055 | 0.85 | KMT2A (0.55) | KMT2AEPHX2OPRD1CASP3FABP7 | |
| SCHEMBL14485271 | 0.85 | KMT2A (0.59) | KMT2AEPHX2OPRD1CASP3FABP7 | |
| SCHEMBL32671446 | 0.84 | KMT2A (0.51) | KMT2AEPHX2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023281480-A1 | CONJUGATES OF CHECKPOINT INHIBITORS WITH IL-2, AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-01-12 | — | — | WO | disclosed |